ALGS
Aligos Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$6.21
−0.16%Next report
Analyst consensus
- Next report date
- Nov 5, 2026
- EPS estimate
- -$2.44
- Revenue estimate
- $4.8M
Latest reported
- Last report date
- Aug 6, 2026
- EPS actual
- -$0.14
- EPS estimate
- -$1.09
- Revenue actual
- $27.8M
- Revenue estimate
- $24.7M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 8
- EPS misses (12Q)
- 4
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +13.5%
- Revenue beats (12Q)
- 9
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 5, 2026